Cargando…

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance

The activation of the Notch pathway induces glioblastoma (GBM) development. Since KDEL (Lys-Asp-Glu-Leu) containing 2 (KDELC2) is involved in the Notch pathway, the detailed mechanism is still undetermined. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases revealed that...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Yu-Ling, Chang, Hsin-Han, Chen, Ying-Chuan, Chang, Yu-Chan, Chen, Ying, Tsai, Wen-Chiuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555920/
https://www.ncbi.nlm.nih.gov/pubmed/32927743
http://dx.doi.org/10.3390/biomedicines8090339
_version_ 1783594119446134784
author Tsai, Yu-Ling
Chang, Hsin-Han
Chen, Ying-Chuan
Chang, Yu-Chan
Chen, Ying
Tsai, Wen-Chiuan
author_facet Tsai, Yu-Ling
Chang, Hsin-Han
Chen, Ying-Chuan
Chang, Yu-Chan
Chen, Ying
Tsai, Wen-Chiuan
author_sort Tsai, Yu-Ling
collection PubMed
description The activation of the Notch pathway induces glioblastoma (GBM) development. Since KDEL (Lys-Asp-Glu-Leu) containing 2 (KDELC2) is involved in the Notch pathway, the detailed mechanism is still undetermined. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases revealed that KDELC2 mRNA was associated with oncologic factors of GBM. U87, LN229, LNZ308, U118MG, and GBM8401 cells showed higher KDELC2 expression than normal brain tissues. The results of MTT, wound healing, and invasion assays proved that KDELC2 knockdown suppressed GBM-aggressive behaviors. The inhibitory properties of GBM stemness and angiogenesis under KDELC2 knockdown were evaluated by tumor spheroid and tube formation assays. Suppression of KDELC2 downregulated Notch factors’ expressions, including KDELC1, pofut1, Notch receptors 1–3, and HES-1. Immunoblot assay showed that KDELC2 knockdown promoted tumor apoptosis by downregulating PI3k/mTOR/Akt, MAPK/ERK, and NF-kB pathways. The combination of KDELC2 knockdown and temozolomide (TMZ) treatment had an optimal therapeutic effect by suppressing MGMT expression. Results of an orthotopic xenograft animal model and human tissue confirmed that KDELC2 correlated with glioma proliferation, advanced grades, and poor prognosis. Therefore, KDELC2 might be a potential pharmacological target to inhibit tumorigenesis, epithelial–mesenchymal transition, angiogenesis, and chemo-resistance of GBM.
format Online
Article
Text
id pubmed-7555920
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75559202020-10-19 Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance Tsai, Yu-Ling Chang, Hsin-Han Chen, Ying-Chuan Chang, Yu-Chan Chen, Ying Tsai, Wen-Chiuan Biomedicines Article The activation of the Notch pathway induces glioblastoma (GBM) development. Since KDEL (Lys-Asp-Glu-Leu) containing 2 (KDELC2) is involved in the Notch pathway, the detailed mechanism is still undetermined. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases revealed that KDELC2 mRNA was associated with oncologic factors of GBM. U87, LN229, LNZ308, U118MG, and GBM8401 cells showed higher KDELC2 expression than normal brain tissues. The results of MTT, wound healing, and invasion assays proved that KDELC2 knockdown suppressed GBM-aggressive behaviors. The inhibitory properties of GBM stemness and angiogenesis under KDELC2 knockdown were evaluated by tumor spheroid and tube formation assays. Suppression of KDELC2 downregulated Notch factors’ expressions, including KDELC1, pofut1, Notch receptors 1–3, and HES-1. Immunoblot assay showed that KDELC2 knockdown promoted tumor apoptosis by downregulating PI3k/mTOR/Akt, MAPK/ERK, and NF-kB pathways. The combination of KDELC2 knockdown and temozolomide (TMZ) treatment had an optimal therapeutic effect by suppressing MGMT expression. Results of an orthotopic xenograft animal model and human tissue confirmed that KDELC2 correlated with glioma proliferation, advanced grades, and poor prognosis. Therefore, KDELC2 might be a potential pharmacological target to inhibit tumorigenesis, epithelial–mesenchymal transition, angiogenesis, and chemo-resistance of GBM. MDPI 2020-09-10 /pmc/articles/PMC7555920/ /pubmed/32927743 http://dx.doi.org/10.3390/biomedicines8090339 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tsai, Yu-Ling
Chang, Hsin-Han
Chen, Ying-Chuan
Chang, Yu-Chan
Chen, Ying
Tsai, Wen-Chiuan
Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
title Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
title_full Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
title_fullStr Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
title_full_unstemmed Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
title_short Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
title_sort molecular mechanisms of kdelc2 on glioblastoma tumorigenesis and temozolomide resistance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555920/
https://www.ncbi.nlm.nih.gov/pubmed/32927743
http://dx.doi.org/10.3390/biomedicines8090339
work_keys_str_mv AT tsaiyuling molecularmechanismsofkdelc2onglioblastomatumorigenesisandtemozolomideresistance
AT changhsinhan molecularmechanismsofkdelc2onglioblastomatumorigenesisandtemozolomideresistance
AT chenyingchuan molecularmechanismsofkdelc2onglioblastomatumorigenesisandtemozolomideresistance
AT changyuchan molecularmechanismsofkdelc2onglioblastomatumorigenesisandtemozolomideresistance
AT chenying molecularmechanismsofkdelc2onglioblastomatumorigenesisandtemozolomideresistance
AT tsaiwenchiuan molecularmechanismsofkdelc2onglioblastomatumorigenesisandtemozolomideresistance